Eli Lilly and Co (STU:LLY) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:LLY Eli Lilly and Co STU:LLY
92 GF Score
Price €1,025.00
GF Value €1,253.45
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (STU:LLY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.14 13.57 20.20 23.93 28.40

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.34 20.92 28.40 22.92 28.25

STU:LLY vs JNJ, ABBV, MRK: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


STU:LLY
92GF Score
Eli Lilly and Co STU:LLY
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=22.313/333.9520*333.9520
=22.313

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.361 241.428 6.032
201612 5.132 241.432 7.099
201703 4.628 243.801 6.339
201706 4.904 244.955 6.686
201709 4.495 246.819 6.082
201712 2.642 246.524 3.579
201803 3.835 249.554 5.132
201806 4.641 251.989 6.151
201809 4.431 252.439 5.862
201812 4.852 251.233 6.450
201903 4.580 254.202 6.017
201906 5.395 256.143 7.034
201909 5.414 256.759 7.042
201912 6.010 256.974 7.810
202003 5.817 258.115 7.526
202006 5.361 257.797 6.945
202009 5.348 260.280 6.862
202012 6.689 260.474 8.576
202103 6.266 264.877 7.900
202106 6.145 271.696 7.553
202109 6.321 274.310 7.695
202112 7.648 278.802 9.161
202203 7.824 287.504 9.088
202206 6.798 296.311 7.662
202209 7.757 296.808 8.728
202212 7.617 296.797 8.571
202303 7.197 301.836 7.963
202306 8.499 305.109 9.302
202309 9.891 307.789 10.732
202312 9.489 306.746 10.331
202403 8.925 312.332 9.543
202406 11.613 314.175 12.344
202409 11.389 315.301 12.063
202412 14.309 315.605 15.141
202503 13.074 319.799 13.653
202506 14.991 322.561 15.520
202509 16.684 324.800 17.154
202512 18.345 324.054 18.905
202603 19.116 330.213 19.332
202606 22.313 333.952 22.313

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Eli Lilly and Co (STU:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,025.00 is trading 18.2% below its estimated GF Value™ of €1,253.45. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for STU:LLY:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €1,253.45 vs. price of €1,025.00 (18.2% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the STU:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
92GF Score

Get the complete analysis for STU:LLY

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,025.00
Price
€1,253.45
GF Value